Skip to main content
. 2022 Jun 14;14(1):2079449. doi: 10.1080/19420862.2022.2079449

Figure 7.

A timeline from 1980 until 2022. The timeline is annotated with hallmark papers for experimental milestones in antibody sequencing, genomics, and M S based protein sequencing. A bar graph showing an exponential growth of the number of registered antibody drugs from 1994 onwards up to around 700 total registered mAbs. There is a line showing the registrations for each given year which also steadily increases.

Timeline of key developments paving the way toward MS-based de novo sequencing of serum antibodies. Blue: Key developments in the field of genomic sequencing. Green: Key advances in the field of antibody research. Orange: Selected hallmark papers in the field of MS-based antibody sequencing. To visualize the impact of therapeutic antibody development, the bar graph indicates the cumulative number of registered antibody-based drugs, and the line shows the number of registrations for a given year.4